Pharmaceutical News

August 18, 2021
Heart-Failure-Indication

Jardiance Receives New Heart Failure Indication

August 18, 2021 – Jardiance® (empagliflozin) 10mg, manufactured by Boehringer Ingelheim and Eli Lilly, is now U.S. FDA approved to reduce the risk of cardiovascular death plus hospitalization